SOUTH PLAINFIELD, N.J., June 15, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 12, 2023, the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon … Read more
– Preclinical and early research gene therapy programs discontinued –– Expected reductions of approximately 15% in residual 2023 OPEX – SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue … Read more
– Conference call and webcast to be held at 5:00 pm EDT – SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The study did not meet its primary endpoint of statistically significant change in mFARS score … Read more
– Highly statistically significant and clinically meaningful results – – 63% mean blood Phe reduction in primary analysis population (p<0.0001) – – Conference call and webcast to be held at 8:00 AM EDT – SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in … Read more